

## REFERENCES

1. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. *Drug*. 1998; 56: 989-1007.
2. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation*. 1984; 70: 580-587.
3. Rich S, Kaufmann E, Levy PS. The effect of high dose of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med*. 1992; 327: 76-81.
4. Barst BJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD Jr, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med*. 1996; 334: 296-301.
5. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. *Circulation*. 1982; 66: 334-338.
6. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. *J Cardiovasc Pharmacol*. 1993; 22(Suppl. 4): S1-14.
7. Christman BW, McPherson D, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolite in pulmonary hypertension. *N Engl J Med*. 1992; 327: 70-75.

8. Watkins WD, Peterson MB, Crone RK, Shanonn DC, Levine L. Prostacyclin and prostaglandin E<sub>1</sub> for severe idiopathic pulmonary artery hypertension. *Lancet*. 1980; I: 1083.
9. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. *Chest* 1999; 116: 914-920.
10. Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatment for severe pulmonary hypertension. *Br Heart J*. 1993; 70: 366-370.
11. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage B. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion. *J Am Coll Cardiology*. 1997; 30: 343-349.
12. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. *N Engl J Med*. 1998; 338: 273-277.
13. Magnani B, Galie N. Prostacyclin in primary pulmonary hypertension. *Eur Heart J*. 1996; 17: 18-24.
14. Miyata M, Ueno Y, Sekine H, Ito O, Sakuma F, Koike H, Nishio S, Nishimaki T, Kasukawa R. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. *J Cardiovasc Pharmacol*. 1996; 27: 20-26.
15. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new

- oral PGI<sub>2</sub> analogue, beraprost, in primary and secondary pulmonary hypertension. *Am J Cardiol.* 1996; 78: 244-247.
16. Nishio S, Matsuura H, Kawai N, Fukatsu Y, Hirano T, Nishikawa N, Kaneoka K, Uematsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. *Jpn J Pharmacol.* 1988; 47: 1-10.
17. Hashida H, Hamada M, Shigematsu Y, Ikeda S, Kuwahara T, Kawakami H, Hara Y, Kodama K, Kohara K, Hiwada K. Beneficial hemodynamic effects of oral prostacyclin (PGI<sub>2</sub>) analogue, beraprost sodium, on a patient with primary pulmonary hypertension; A case report. *Angiology.* 1998; 49: 161-164.
18. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature.* 1988; 332: 411-415.
19. Miyauchi T, Masaki T. Pathophysiology of endothelin in cardiovascular system. *Annu. Rev. Physiol.* 1999; 61: 391-415.
20. Miyauchi T, Goto K. Heart failure and endothelin receptor antagonists. *Trends Pharmacol Sci.* 1999;20:210-217.
21. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. *J Biol Chem.* 1990; 265: 20555-20562.
22. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? *Ann Intern Med.* 1991; 114: 464-469.

23. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-like immunoreactivity in the lung in congestive heart failure in rats. *J Am Coll Cardiol.* 1996; 28: 1580-1588.
24. Ishikawa S, Miyauchi T, Sakai S, Ushinohama H, Sagawa K, Fusazaki N, Kado H, Sunagawa H, Honda S, Ueno H, Yamaguchi I, Sugishita Y, Goto K. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. *J Thorac Cardiovasc Surg.* 1995; 110: 271-273.
25. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. *Circ Res.* 1993; 73: 887-897.
26. Miyauchi T, Sato R, Sakai S, Kobayashi T, Ueno M, Kondo H, Kawano S, Goto K, Yamaguchi I. Contribution of endogenous endothelin-1 to the progression of right-sided heart failure caused by pulmonary hypertension in rats: Improvement of survival and of failing right ventricular gene expression by chronic treatment. *Circulation.* 1999; 100(Suppl. I): I-272.
27. Bonvallet ST, Zamora MR, Hasunuma K, Sato K, Hanasato N, Anderson D, Sato K, Stelzner TJ. BQ132, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. *Am J Physiol.* 1994; 266 (*Heart Circ Physiol* 35): H1327-H1331.
28. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. *J Appl Physiol.* 1995,

79: 2122-2131.

29. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, Leier CV, Loh Evan, Nicklas JM, Lewis BE. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. *Circulation*. 2000; 101: 2922-2927.
30. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Distribution of endothelin-1 in the lung of the rats with pulmonary hypertension of different etiology. *Int J Angiol*. 1998, 7: 160-164.
31. Ueno M, Miyauchi T, Sakai S, Kobayashi T, Goto K, Yamaguchi I. Effects of physiological or pathological pressure load *in vivo* on myocardial expression of ET-1 and receptors. *Am J Physiol*. 1999; 277 (*Regulatory Integrative Comp Physiol* 46): R1321-R1330.
32. Miyauchi T, Sato R, Sakai S, Kobayashi T, Ueno M, Kondo H, Kawano S, Goto K, Yamaguchi I. Endothelin-1 and right-sided heart failure in rats: Effects of an endothelin receptor antagonist on the failing right ventricle. *J Cardiovasc Pharmacol*. 2000; 36(Suppl. 1): S327-330.
33. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. *Am J Physiol*. 1981; 240 (*Heart Circ Physiol* 9): H149-H155.
34. Merkow L, Kleinerman J. An electron microscopic study of pulmonary vasculitis induced by monocrotaline. *Lab Invest*. 1966; 15: 547-564.
35. Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. *J Pharmacol Exp Ther*. 1998; 286: 643-649.

36. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, Yabana H, Goto K, Sugishita Y, Murata S. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. *Circulation*. 1999; 99: 2171-2176.
37. King ME, Braun H, Goldblatt A, Liberthson R, Weyman AE. Interventricular septal configuration as a predictor of right ventricular systolic hypertension in children: a cross-sectional echocardiographic study. *Circulation*. 1983; 68: 68-75.
38. Ivy DD. Echocardiographic evaluation of pulmonary hypertension. In: Echocardiographic evaluation of congenital heart disease, edited by Lilliam MV, Raul OC. Philadelphia, NY, USA. Lippincott Raver: 1999. 537-547.
39. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. *Nature*. 1996; 384: 353-355.
40. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: Marked increase in endothelin-1 production in the failing heart. *Circulation*. 1996; 93: 1214-1222.
41. Sakai S, Miyauchi T, Kobayashi T, Yamaguchi I, Goto K, Sugishita Y. Altered expression of isoform of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist. *J Cardiovasc Pharmacol*. 1998; 31(Suppl. 1): S302-305.

42. Sakai S, Miyauchi T, Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. *Circulation*. 2000; 101: 2849-2853.
43. Kraft R, Bravo-Zehnder M, Taylor DA, Leinwand LA. Complete nucleotide sequence of full length cDNA for rat beta cardiac myosin heavy chain. *Nucleic Acids Res*. 1989; 17: 7529-30.
44. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A<sub>2</sub>, and prostacyclin. *Pharmacol Rev*. 1979, 30: 293-331.
45. Shaul PW, Kinane B, Farrar MA, Buja LM, Magness RR. Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. *J Clin Invest*. 1991, 88: 447-455.
46. Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. *Cardiovasc Res*. 1999; 44: 274-282.
47. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA, Levin ER. Prostaglandin E<sub>2</sub> and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. *J Biol Chem*. 1994, 269: 11938-11944.
48. Nakaki T, Ohta M, Kato R. Inhibition of endothelin-1-induced DNA synthesis by prostacyclin and its stable analogues in vascular smooth muscle cells. *J Cardiovasc Pharmacol*. 1991; 17(Suppl. 7): S177-178.
49. Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Trusler GA, Rowe RD, Olley PM,

- Cutz E. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: A correlation of light with scanning electron microscopy and transmission electron microscopy. *Lab Invest.* 1986; 55: 632-653.
50. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. *Eur Respir J.* 1996; 9: 356-363.
51. Nagaya N, Yokohama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, Tanabe T. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. *Circulation.* 2000; 102: 2005-2010.
52. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. *Annu Rev Physiol* 1993, 55: 55-75
53. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y, Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. *Circulation.* 1994; 89: 2198-2203.
54. Nihill MR. Clinical management of patients with pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children, and adolescents: Including the fetus and young adult. fifth edition Vol.2, edited by Emmanouilides GC, Riemenschneider TA, Allen HD, Gutgesell HP. Maryland, USA. Williams & Wilkins; 1995. 1695-1711.